Search Result

Results for "

Aβ42

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Adenosine Receptor (1) Amyloid-β (64) Apoptosis (8) ATM/ATR (1) Autophagy (1) Beta-secretase (1) Cathepsin (2) Cholinesterase (ChE) (8) COMT (4) COX (1) Drug Derivative (1) Drug Metabolite (1) EGFR (1) Formyl Peptide Receptor (FPR) (2) HIV (2) iGluR (3) Interleukin Related (1) Isotope-Labeled Compounds (2) Lactate Dehydrogenase (1) Monoamine Oxidase (1) mTOR (3) NO Synthase (1) NOD-like Receptor (NLR) (2) Notch (4) Organoid (1) Phosphatase (1) Phospholipase (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Sigma Receptor (1) Somatostatin Receptor (1) Tau Protein (4) γ-secretase (27)
By Research Areas:	Cancer (10) Infection (2) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (87)

By Targets:

11β-HSD (1)

Adenosine Receptor (1)

Amyloid-β (64)

Apoptosis (8)

ATM/ATR (1)

Autophagy (1)

Beta-secretase (1)

Cathepsin (2)

Cholinesterase (ChE) (8)

COMT (4)

COX (1)

Drug Derivative (1)

Drug Metabolite (1)

EGFR (1)

Formyl Peptide Receptor (FPR) (2)

HIV (2)

iGluR (3)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

Lactate Dehydrogenase (1)

Monoamine Oxidase (1)

mTOR (3)

NO Synthase (1)

NOD-like Receptor (NLR) (2)

Notch (4)

Organoid (1)

Phosphatase (1)

Phospholipase (1)

Ras (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Sigma Receptor (1)

Somatostatin Receptor (1)

Tau Protein (4)

γ-secretase (27)

By Research Areas:

Cancer (10)

Infection (2)

Inflammation/Immunology (5)

Metabolic Disease (3)

Neurological Disease (87)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149763

Aβ42 agonist-1	Amyloid-β	Neurological Disease
Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-149764

Aβ42 agonist-2	Amyloid-β	Neurological Disease
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-136866

Aβ42-IN-2	γ-secretase	Neurological Disease
Aβ42-IN-2 (compound example 36) is a γ-secretase modulator. Aβ42-IN-2 has an IC₅₀ of 6.5 nM for Αβ₄₂. Aβ42-IN-2 can be used for the research of Alzheimer's disease .

HY-111267

Aftin-4	Amyloid-β	Neurological Disease
Aftin-4 is an *Amyloid-β₄₂* (Aβ₄₂) inducer.

HY-P4295

Z-Phe-Ala-diazomethylketone PADK	Cathepsin γ-secretase	Neurological Disease
Z-Phe-Ala-diazomethylketone binds directly to Aβ42 monomers and small oligomers. Z-Phe-Ala-diazomethylketone inhibits the formation of Aβ42 dodecamers and inhibits Aβ42 fibril formation in the solution. Z-Phe-Ala-diazomethylketone has the potential for neurodegenerative disorders research .

HY-130609A

Aβ42-IN-1 free base	γ-secretase	Neurological Disease
Aβ42-IN-1 free base (compound 1v) is an orally active, high brain exposure γ-secretase modulator. Aβ42-IN-1 free base potently reduces Aβ42 levels with an IC₅₀ value of 0.091 μM, and significantly reduces brain Aβ42 levels in mice. Aβ42-IN-1 free base is a promising compound for the treatment of Alzheimer’s disease .

HY-130609

Aβ42-IN-1	γ-secretase	Neurological Disease
Aβ42-IN-1, compound 1v, is a novel, potent and orally active?γ-secretase modulator (GSM). Aβ42-IN-1 potently reduced Aβ42 levels with an IC₅₀?value of 0.091?μM without CYP3A4 inhibition. Aβ42-IN-1 shows a sustained pharmacokinetic profile.

HY-161109

Aβ42-IN-4	Amyloid-β	Neurological Disease
Aβ42-IN-4 (compound 0043) degrades amyloid precursor protein (APP) and reduces Aβ42 production .

HY-13325

Aβ42-IN-6	Drug Derivative	Others
Aβ42-IN-6 is an active compound.

HY-144752

cSPM Cyclic spermine	Amyloid-β	Neurological Disease
cSPM (Cyclic spermine) is a Aβ42 inhibitor. cSPM could suppress the aggregation of three different peptides, Aβ42, amylin and insulin, and decreases cytotoxicity .

HY-173282

Aβ aggregation-IN-2	Amyloid-β	Neurological Disease
Aβ aggregation-IN-2 (Compound 8i) is an inhibitor of amyloid-β protein (Aβ42) aggregation, showing approximately 91% inhibition of Aβ42 aggregation at 25 μM. It also exhibits Aβ42 disaggregation effects and antioxidant activity. Aβ aggregation-IN-2 can be used for research in the field of Alzheimer's disease .

HY-169614

2002-G12	Amyloid-β	Neurological Disease
2002-G12 (compound 5a) is an Aβ42 inhibitor that can reduce Aβ42 toxicity by 76%. 2002-G12 can be used in Alzheimer's research .

HY-146139

Aβ-IN-3	Amyloid-β	Neurological Disease
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-146140

Aβ-IN-4	Amyloid-β	Neurological Disease
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-111911

Xanthocillin X permethyl ether	Amyloid-β	Neurological Disease
Xanthocillin X permethyl ether is a natural compound isolated from fungal extracts, with Aβ-42 lowering activity .

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Amyloid-β	Neurological Disease
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-103241

Ro 90-7501 3 Publications Verification	Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 is an *amyloid β₄₂* (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂**-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-119196

Caprospinol SP-233	Amyloid-β Sigma Receptor	Others
Caprospinol (SP-233) is a steroid compound candidate based on the structure of 22R-hydroxycholesterol. It has multiple mechanisms of neuroprotection, including binding to β-amyloid protein (Aβ(42)), interacting with the mitochondrial respiratory chain, clearing Aβ(42) monomers, and acting as a σ-1 receptor ligand. It can cross the blood-brain barrier in vivo and restore cognitive impairment, and has the potential to inhibit Alzheimer's disease.

HY-108714

NGP555	γ-secretase	Neurological Disease
NGP555 is a γ-secretase modulator. NGP555 Lowers the Amyloid Biomarker Aβ42 .

HY-112282

BI-1408	γ-secretase Amyloid-β	Neurological Disease
BI-1408 is a potent γ secretase modulator with an IC₅₀ of 0.04 μM for Aβ₄₂ .

HY-P10799

SLAFVDVLN	Amyloid-β	Neurological Disease Metabolic Disease
SLAFVDVLN, a molecular peptide, is a BACE-1 inhibitor with a K_i value of 94 nM. SLAFVDVLN can reduce Aβ42 production .

HY-153255

BACE1-IN-13	Beta-secretase	Neurological Disease
BACE1-IN-13 (Compound 36) is an orally active BACE1 inhibitor with an IC₅₀ value of 2.9 nM. BACE1-IN-13 is highly potent in hAβ42 cell (IC₅₀ = 1.3 nM). BACE1-IN-13 has cardiovascularly safty and elicits sustained Aβ42 reduction in mouse and dog animal models .

HY-136674

Aftin-5	Amyloid-β	Neurological Disease
Aftin-5 is an inducer for Amyloid-β 42 (Aβ42). Aftin-5 upregulates Aβ42 and downregulates Aβ38 levels in a β-secretase- and γ-secretase-dependent manner by altering the ultrastructure of mitochondria. Aftin-5 exhibits slightly cytotoxicity in cell SH-SY5Y, HT22, N2a and N2a-AβPP695, with IC₅₀s of 180, 194, 178 and 150 μM, respectively .

HY-120449

AZ4800	Amyloid-β	Others
AZ4800 is a combined inhibitor of two targets in the amyloid precursor protein processing process with additive lowering activity on Aβ42 levels in vitro and in vivo.

HY-146151

γ-Secretase modulator 12	γ-secretase Amyloid-β	Neurological Disease
γ-Secretase modulator 12 (Compound 1a) is a γ-secretase modulator that can selectively decrease *amyloid-β42* (Aβ42) levels (IC₅₀** of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice .

HY-19550

PF-06442609	γ-secretase	Neurological Disease
PF-06442609 is an orally active γ secretase modulator, with an IC₅₀ of 6 nM for Aβ42. PF-06442609 possesses brain good penetration .

HY-171349

Amyloid-β-IN-3	γ-secretase Amyloid-β	Neurological Disease
Amyloid-β-IN-3 (EX.113) is a selective γ-secretase inhibitor. Amyloid-β-IN-3 inhibits Aβ42 secretion in H4 cells with an EC₅₀ value of 148 nM. Amyloid-β-IN-3 regulates the γ-secretase catalytic activity to decrease Aβ42 production, thereby alleviating neurotoxicity caused by Aβ deposition. Amyloid-β-IN-3 is promising for research of Alzheimer's disease (AD) .

HY-114508

Dihydrochalcone 3-Phenylpropiophenone; β-Phenylpropiophenone	Amyloid-β	Neurological Disease
Dihydrochalcone (3-Phenylpropiophenone) is a BBB-penatrable Aβ aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree .

HY-P3793

Amyloid β-Protein (33-42) (TFA)	Amyloid-β	Neurological Disease
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity .

HY-117482A

BPN-15606 besylate	γ-secretase	Neurological Disease
BPN-15606 besylate is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC₅₀ values of 7 nM and 17nM, respectively. BPN-15606 besylate lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 besylate has acceptable PK/PD properties, including bioavailability, half-life, and clearance .

HY-117482

BPN-15606	γ-secretase	Neurological Disease
BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC₅₀ values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance .

HY-P3307

Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2	Tau Protein	Neurological Disease
Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is serum stable, non-toxic to neuronal cells, and selectivity inhibits the fibrilization of tau over Aβ₄₂.

HY-N0373

Licochalcone B 5+ Cited Publications	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-156179

DDC 2′,3′-O-disulfate	Amyloid-β	Neurological Disease
DDC 2′,3′-O-disulfate (compound 4) prevents the fibrillization and oligomerization of Aβ42. DDC 2′,3′-O-disulfate has the potential for Alzheimer's disease (AD) research .

HY-N0116

Hematoxylin 5+ Cited Publications Natural Black 1; Haematoxylin	Amyloid-β	Others
Hematoxylin (Natural Black 1), a naturally occurring flavonoid compound derived from Caesalpinia sappan Linn.. Hematoxylin is a nuclear stain in histology and is also a potent Aβ42 fibrillogenesis inhibitor with an IC₅₀ of 1.6 μM.

HY-128581

γ-Secretase modulator 4	γ-secretase	Neurological Disease
γ-Secretase modulator 4 is a potent γ-secretase modulator, reduces the Aβ42 level with IC₅₀s of 0.014 μM and 0.017 μM in human and mouse, respectively .

HY-B0034

Donepezil Hydrochloride 10+ Cited Publications E2020	Cholinesterase (ChE)	Neurological Disease Cancer
Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-153986

AEP-IN-2	Cathepsin	Neurological Disease
AEP-IN-2 is an asparagine endopeptidase (AEP) inhibitor via block AEP cleavage of APP and Tau. AEP-IN-2 has oral activity and decreases Aβ40 and Aβ42 and p-Tau levels .

HY-123228

CHF5022	Amyloid-β	Neurological Disease
CHF5022 is an inhibitor of Aβ42 secretion (IC₅₀=92 μM). CHF5022 retains a modest activity on Aβ40 at non-cytotoxic concentrations (−22.2±4.8% at 100 μM) .

HY-108499

NNC 26-9100	Somatostatin Receptor Amyloid-β	Neurological Disease
NNC 26-9100 is a selective somatostatin sst4 receptor full agonist (K_i: 6 nM, EC₅₀: 2 nM). NNC 26-9100 decreases total soluble Aβ42, increases brain neprilysin activity and improves learning .

HY-N0373R

Licochalcone B (Standard)	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B (Standard) is the analytical standard of Licochalcone B. This product is intended for research and analytical applications. Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-N9861

Kayaflavone	Amyloid-β	Neurological Disease
Kayaflavone is an amentoflavone type biflavonoid. Kayaflavone has an inhibitory activity against *amyloid-β42* cytotoxicity in PC-12 cells with an EC₅₀ value of 5.29 μΜ. Kayaflavone is promising for research of Alzheimer’s disease .

HY-156180

DDC 3′-O-β-D glucuronide	Drug Metabolite	Neurological Disease
DDC 3′-O-β-D glucuronide (compound 5) is a drug metabolite that can prevent the fibrillization and oligomerization of Aβ42. DDC 3′-O-β-D glucuronide has potential for the research of Alzheimer's disease .

HY-146251

BuChE-IN-6	Cholinesterase (ChE) Amyloid-β	Neurological Disease
BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ₄₂ self-aggregation .

HY-139142B

Simufilam hydrochloride 1 Publications Verification PTI-125 hydrochloride	mTOR iGluR Amyloid-β Tau Protein	Neurological Disease
Simufilam hydrochloride (PTI-125 hydrochloride) is an orally active FLNA modulator. Simufilam hydrochloride restores NMDAR signaling and Arc expression. Simufilam hydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ₄₂-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride can be used for research of Alzheimer's disease .

HY-139142

Simufilam 1 Publications Verification PTI-125	mTOR iGluR Amyloid-β Tau Protein	Neurological Disease
Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ₄₂-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam can be used for research of Alzheimer's disease .

HY-139142A

Simufilam dihydrochloride PTI-125 dihydrochloride	Tau Protein Amyloid-β mTOR iGluR	Neurological Disease
Simufilam dihydrochloride (PTI-125 dihydrochloride) is an orally active FLNA modulator. Simufilam dihydrochloride restores NMDAR signaling and Arc expression. Simufilam dihydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ₄₂-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam dihydrochloride can be used for research of Alzheimer's disease .

HY-10016

E 2012 5+ Cited Publications	γ-secretase	Neurological Disease
E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .

HY-B1786A

(E/Z)-Sulindac sulfide	γ-secretase Amyloid-β	Neurological Disease
(E/Z)-Sulindac sulfide is a potent γ-secretase modulator (GSM). (E/Z)-Sulindac sulfide selectively reduces Aβ42 production in favor of shorter Aβ species. (E/Z)-Sulindac sulfide can be used for researching Alzheimer’s disease .

Cat. No.	Product Name	Type

HY-N0116

Hematoxylin 5+ Cited Publications Natural Black 1; Haematoxylin	Chromogenic Substrates
Hematoxylin (Natural Black 1), a naturally occurring flavonoid compound derived from Caesalpinia sappan Linn.. Hematoxylin is a nuclear stain in histology and is also a potent Aβ42 fibrillogenesis inhibitor with an IC₅₀ of 1.6 μM.

Cat. No.	Product Name	Target	Research Area

HY-P4295

Z-Phe-Ala-diazomethylketone PADK	Cathepsin γ-secretase	Neurological Disease
Z-Phe-Ala-diazomethylketone binds directly to Aβ42 monomers and small oligomers. Z-Phe-Ala-diazomethylketone inhibits the formation of Aβ42 dodecamers and inhibits Aβ42 fibril formation in the solution. Z-Phe-Ala-diazomethylketone has the potential for neurodegenerative disorders research .

HY-P5905

Citrullinated amyloid-β (1-42) peptide (human) 1 Publications Verification Citrullinated Aβ (1-42); Citrullinated Aβ42	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-42) peptide (human) (Citrullinated Aβ (1-42)) is a modified form of β-Amyloid (1-42) (HY-P1363) with a citrullination at the Arg5 site. Compared to the unmodified β-Amyloid (1-42), its formation of soluble low-molecular-weight oligomers is enhanced, the rate of fibril formation is reduced, and like unmodified Aβ42, it forms protofibrils comprised of parallel β-sheets .

HY-P1119

WRW4 Maximum Cited Publications 7 Publications Verification	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P10799

SLAFVDVLN	Amyloid-β	Neurological Disease Metabolic Disease
SLAFVDVLN, a molecular peptide, is a BACE-1 inhibitor with a K_i value of 94 nM. SLAFVDVLN can reduce Aβ42 production .

HY-P3793

Amyloid β-Protein (33-42) (TFA)	Amyloid-β	Neurological Disease
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity .

HY-P3307

Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2	Tau Protein	Neurological Disease
Ac-Val-Gln-aIle-Val-aTyr-Lys-NH2 is serum stable, non-toxic to neuronal cells, and selectivity inhibits the fibrilization of tau over Aβ₄₂.

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P3781

(Met(O)35)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .

HY-P10824

RI-OR2-TAT	Amyloid-β	Neurological Disease
RI-OR2-TAT is a brain-penetrant inhibitor of β-Amyloid oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a K_d value of 58-125 nM. RI-OR2-TAT reduces Aβ aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus .

HY-P1119A

WRW4 TFA	Formyl Peptide Receptor (FPR)	Neurological Disease
WRW4 TFA, a specific formyl peptide receptor-like 1 (FPRL1) antagonist, inhibits WKYMVm binding to FPRL1 with an IC₅₀ of 0.23 μM. WRW4 TFA specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid beta42 (Abeta42) peptide, and F peptide .

Cat. No.	Product Name	Target	Research Area

HY-P990078

Remternetug LY3372993	Amyloid-β	Neurological Disease
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ. Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research .

HY-P991073

MEDI-1814	Amyloid-β	Neurological Disease
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-111911

Xanthocillin X permethyl ether	Structural Classification Microorganisms Antifungal Antibiotics Source classification Disease Research Other Antibiotics	Amyloid-β
Xanthocillin X permethyl ether is a natural compound isolated from fungal extracts, with Aβ-42 lowering activity .

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Structural Classification other families Source classification Plants Steroids	Amyloid-β
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .

HY-N0373

Licochalcone B 5+ Cited Publications	Structural Classification Chalcones Flavonoids Leguminosae Source classification Plants Glycyrrhiza uralensis Fisch.	Amyloid-β Apoptosis NOD-like Receptor (NLR)
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-N0116

Hematoxylin 5+ Cited Publications Natural Black 1; Haematoxylin	Structural Classification Classification of Application Fields Leguminosae Caesalpinia sappan L. Source classification Other Diseases Phenols Polyphenols Plants Disease Research Fields	Amyloid-β
Hematoxylin (Natural Black 1), a naturally occurring flavonoid compound derived from Caesalpinia sappan Linn.. Hematoxylin is a nuclear stain in histology and is also a potent Aβ42 fibrillogenesis inhibitor with an IC₅₀ of 1.6 μM.

HY-N0373R

Licochalcone B (Standard)	Structural Classification Chalcones Flavonoids Leguminosae Source classification Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch.	Amyloid-β Apoptosis NOD-like Receptor (NLR)
Licochalcone B (Standard) is the analytical standard of Licochalcone B. This product is intended for research and analytical applications. Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-N9861

Kayaflavone	Ranunculus ternatus Thunb. Structural Classification Flavonoids Flavones Ranunculaceae Source classification Plants	Amyloid-β
Kayaflavone is an amentoflavone type biflavonoid. Kayaflavone has an inhibitory activity against *amyloid-β42* cytotoxicity in PC-12 cells with an EC₅₀ value of 5.29 μΜ. Kayaflavone is promising for research of Alzheimer’s disease .

HY-N12321

2',3'-Dihydroxy-4',6'-dimethoxychalcone	Structural Classification Monophenols Labiatae Source classification Phenols Plants Erigeron breviscapus (Vant.) Hand.-Mazz.	Others
2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .

Cat. No.	Product Name	Chemical Structure

HY-B0034S

Donepezil-d5 hydrochloride
Donepezil-d₅ (hydrochloride) is deuterium labeled Donepezil (Hydrochloride). Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-B0034S1

Donepezil-d4 hydrochloride
Donepezil-d₄ (hydrochloride) is the deuterium labeled Donepezil hydrochloride. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-17406S1

Tolcapone-d4

Tolcapone-d₄ is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC₅₀ of 773?nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .

HY-17406S

Tolcapone-d7
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells .

HY-B1588S

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties . Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease . Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD . Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop .Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Aβ42

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products